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BACKGROUND. The incidence of lymph node metastasis is high in patients who
have pT3 gastric cancer. However, the impact of total retrieved lymph nodes
(tLNs) on staging and survival of these patients is not clear.
METHODS. For this study, the authors examined 1895 patients with pT3 gastric
cancer who underwent surgery at Yonsei University Medical College from January
1987 to June 2000.
RESULTS. Four hundred sixty of 1895 patients (24.3%) were diagnosed with
pT3N0 gastric cancer. Patients who had <31 tLNs (25th percentile) had less
advanced lymph node (N) stage than the other patients (P < .001). Lymph node
metastasis had a positive association with the number of tLNs in a logistic
regression analysis (P < .001; hazards ratio, 1.014; 95% confidence interval, 1.006–
1.021). With a median follow-up of 61.1 months, the overall 10-year survival rate
(10-YSR) was 42.8%. Patients with pT3N0 disease who had <31 tLNs had a 10-
YSR of only 55.4%. Although this 10-YSR did not differ significantly from the rate
for patients with N0 disease who had 31 tLNs (65.8%; P 5 .108), it approached
the rate for the N1 group (53.3%; P 5 .207). In multivariable analyses, the number
of tLNs emerged as an independent prognostic predictor in patients with pT3N2
and pT3N3 disease, but not in patients with pT3N0 or pT3N1 disease.
CONCLUSIONS. Increasing numbers of tLNs may improve the accuracy of staging
in patients who have pT3 gastric cancer. Because preoperative lymph node sta-
ging is difficult, a thorough lymph node dissection is mandatory in all serosa-
positive patients. Cancer 2007;110:745–51.  2007 American Cancer Society.
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T he incidence of lymph node metastasis is >70% in patients whohave pT3 gastric cancer, and advanced lymph node (N) stage
(N3) also is frequent.1–3 Based on the International Union against
Cancer (UICC) tumor, lymph node, metastasis (TNM) classification
system, lymph node metastasis increases the tumor severity from
stage II to stage III or even to stage IV.4 Survival is much poorer for
patients who have positive lymph node status.5,6 Thus, N staging in
patients with pT3 gastric cancer, especially for pT3N0 lesions,
should be conducted very carefully.
Since its adoption in 1997, the UICC TNM system (5th edition)
for lymph node involvement of gastric carcinoma has become widely
accepted and is considered superior to the prior classification sys-
tem.7–9 According to this system, >15 retrieved and analyzed lymph
nodes (tLNs) for each patient is required for optimal staging.4,10 How-
ever, because of the extremely high incidence of lymph node metas-
tasis, it is unclear whether 15 tLNs are adequate to accurately stage
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pT3 gastric cancer, especially for pT3N0 lesions. To
the best of our knowledge, there is no such study.
Increasing the number of tLNs, which may pro-
vide an indication of the extent of lymph node dis-
section, reportedly had a survival benefit for certain
subsets of gastric cancer patients who underwent cu-
rative resection.6,11 Thus, we hypothesized that more
tLNs also could lead to a better prognosis for
patients with pT3 disease. The objective of the cur-
rent study was to investigate the impact of increasing
numbers of tLNs on the staging and survival of
patients with pT3 gastric cancer.
MATERIALS AND METHODS
Surgery and Stage Classification
A prospective database was reviewed for this study.
Between January 1987 and June 2000, 5532 patients
with gastric cancer underwent surgery at the Depart-
ment of Surgery, Yonsei University College of Medi-
cine. Of these, 2091 patients had a pathologic
diagnosis of pT3 gastric cancer, because the primary
tumor penetrated the serosa without invading adja-
cent structures.4 One hundred thirty-one patients
who had pT3 gastric cancer with peritoneal and/or
distant metastasis were excluded along with 65
patients who underwent palliative surgery. Finally,
1895 patients were enrolled in this study, including
32 patients who had <15 tLNs. In addition, for the
purposes of comparison, we evaluated 1452 patients
with pT1 disease and 885 patients with pT2 disease
who were enrolled using the same criteria.
All patients in the study underwent the following
standard operations: 1) total or distal subtotal gas-
trectomy, depending on the location and macro-
scopic appearance of the primary tumor, and 2) at
least D2 lymphadenectomy. The definitions for
lymphadenectomy are based on the Japanese
Research Society for Gastric Cancer (JRSGC) rules,
which classify the regional lymph nodes of the stom-
ach into 4 compartments.12 A D2 lymphadenectomy
includes a complete dissection of compartments I
and II; whereas a D3 lymphadenectomy includes a
complete dissection of compartments I, II, and III.
Compartment I consists of perigastric lymph nodes.
Compartment II consists of lymph nodes along the
left gastric artery, the common hepatic artery, the
splenic artery, and around the celiac axis. However,
when the cancer is located in the lower third of the
stomach, lymph nodes along the splenic artery are
classified as located in compartment III. Compart-
ment III also consists of lymph nodes in the hepato-
duodenal ligament, at the posterior aspect of the
head of the pancreas, and at the root of the mesen-
tery. Compartment IV consists of lymph nodes along
the middle colic vessels and paraaortic lymph nodes.
Resected specimens were examined carefully for
accurate pathologic staging according to the JRSGC
rules.12 Depth of invasion was determined precisely
by examining the deepest portion of gastric wall
invasion. The classification of dissected lymph nodes
was verified by surgeons who reviewed the excised
specimens after surgery. All lymph nodes that were
retrieved were stained with hematoxylin and eosin
and were examined for metastasis by specialized
pathologists using light microscopy.
Statistical Analysis
All statistical analyses were conducted using the statis-
tical program, SPSS (version 13.0; SPSS, Chicago, Ill).
Pretreatment characteristics were analyzed using the
2-tailed chi-square test, the Kruskall-Wallis test, and
the 2-tailed t test. The relation between the number of
tLNs and the number of metastatic lymph nodes
(mLNs) was assessed both by correlation test and by
curvilinear regression. Logistic regression was used to
determine the independent risk factors for lymph
node metastasis. Survival analyses were assessed using
the Kaplan-Meier method and a Cox proportional-
hazards regression model. In all statistical analyses, a
P value <.05 was considered significant.
RESULTS
Patient Characteristics
Table 1 provides a detailed description of patient
characteristics. The ratio of men to women was 1.99
to 1 (1262 men and 633 women), and the mean age
was 55 years. The median number of tLNs was 41,
and the 25th and 75th quartiles were 31 tLNs and
53 tLNs, respectively. Four hundred sixty patients
(24.3%) had their disease staged as pT3N0. The inci-
dence of lymph node metastasis was 75.7% in this
study. Six hundred eighty-seven patients (36.3%)
had pT3N1 disease, 435 patients (23.0%) had pT3N2
disease, and 313 patients (16.4%) had pT3N3 dis-
ease; thus, the final stage grouping settled at stage
III or IV.
Correlations Between tLNs and mLNs
The distribution of N stage differed significantly
between patients who had <31 tLNs and all other
patients (P < .001) (Table 1). The patients with <31
tLNs had less advanced disease. The number of
mLNs was correlated highly with the number of tLNs
(P < .001). Curvilinear regression revealed a linear
correlation (R2) between tLNs and mLNs (P < .001;
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R2 5 0.091) (Fig. 1). In univariate analysis, upper-
third tumor location, more aggressive macroscopic
type, larger primary tumor size, and more tLNs were
associated with lymph node metastasis. When a
logistic regression was performed, lymph node me-
tastases were associated with sex (P 5 .029), macro-
scopic type (P 5 .001), tumor size (P < .001), and the
number of tLNs (P < .001; hazards ratio, 1.014; 95%
confidence interval [95% CI], 1.006–1.021) (for
details, see Table 2). When the same logistic regres-
sion model was used to evaluate patients with pT1
and pT2 disease, the number of tLNs did not emerge
as a significant variable in either group (data not
show).
Outcomes
By December 15, 2005 (the cut-off date for this
study), the median follow-up was 61.1 months (95%
CI, 53.3–69 months), and the overall 10-year survival
rate (10-YSR) was 42.8%. The 10-YSR for patients
with N0, N1, N2, and N3 disease was 62.9%, 53.3%,
29.1%, and 9.1%, respectively (P < .001) (Fig. 2). The
5-YSR was 50.4% for all patients and was 74.0%,
59.8%, 36.7%, 14.4% for patients with N0, N1, N2,
and N3 disease, respectively (P < .001). The patients
with pT3N0 disease who had <31 tLNs (25th percen-
tile; N 5 121 patients) had a 10-YSR of 55.4%.
Although this 10-YSR did not differ significantly from
the 10-YSR of other N0 patients (65.8%; P 5 .108;




No. of patients (%)
PAll tLN 30 tLN >30
Total no. 1895 432 1463
Mean age, y 55 56 55 .062
Gender
Men 1262 276 (63.9) 986 (67.4) .543
Women 633 156 (36.1) 477 (32.6)
Macroscopic (Bormann) type
I 94 21 (4.9) 73 (4.99) .375
II 328 88 (20.4) 240 (16.4)
III 1213 271 (62.7) 942 (64.39)
IV 241 48 (11.1) 193 (13.19)
Unknown 19 4 (0.9) 15 (1.03)
Location
Upper third 301 67 (15.5) 234 (15.99) .181
Middle third 753 168 (38.9) 585 (39.99)
Lower third 782 188 (43.5) 594 (40.60)
Diffuse 30 2 (0.5) 28 (1.91)
Unknown 29 7 (1.6) 22 (1.5)
Mean size, cm 5.8 5.3 5.9 <.001
Histologic type
Differentiated 621 146 (33.8) 475 (32.47) .404
Undifferentiated 1270 285 (66) 985 (67.33)
Unknown 4 1 (0.2) 3 (0.21)
Mean no. of tLNs 43 24 46 <.001
Pathologic LN status
pN0 460 121 (28) 339 (23.17) <.001
pN1 687 195 (45.1) 492 (33.63)
pN2 435 96 (22.2) 339 (23.17)
pN3 313 20 (4.6) 293 (20.03)
tLNs indicates total retrieved lymph nodes; LN, lymph node.
FIGURE 1. This scatterplot shows the distribution of metastatic lymph
nodes according to the number of retrieved lymph nodes (tLNs). Curvilinear
regression revealed a linear correlation (R2) between tLNs and metastatic
lymph nodes (P < .001; R2 5 0.091).
TABLE 2
Univariate and Multivariate Analyses of Lymph Node Metastasis by
Logistic Regression
Variable
Univariate analysis Multivariate analysis
P HR 95% CI P
Age* .819
Sexy .103 1.294 1.026–1.631 .029
Macroscopic
(Bormann) type <.001 .001
II{ 1.453 0.866–2.437 .157
III{ 1.902 1.185–3.053 .008
IV{ 3.032 1.687–5.449 <.001
Location .048
Histologic type .075
Size* <.001 1.101 1.050–1.154 <.001
No. of tLNs* <.001 1.014 1.006–1.021 <.001
HR indicates hazards ratio; 95% CI, 95% confidence interval; tLNs, total retrieved lymph nodes.
* Consecutive variables; others were categorized variables.
y Men compared with women.
{ Compared with Bormann type I.
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of the N1 group (53.3%; P 5 .207) (Fig. 3b). Figure 3c
provides a combination of these 2 analyses for a
clear comparison. None of the clinical pathologic
features differed significantly between these 3 groups
(age, P 5 .711; sex, P 5 .068; macroscopic type,
P 5 .073; tumor location, P 5 .073; tumor size,
P 5 .711; and histologic type, P 5 .502). This was not
observed in other lymph node groups (eg, N1
patients who had <31 tLNs compared with N2
patients; both P < .001).
In the pT1 group, the patients with N0 disease
who had <31 tLNs also had a 10-YSR similar to that
of the patients with N1 disease (86.7% vs 83.9%,
respectively; P 5 .470); however, in our database, the
overall 10-YSR for all patients with pT1N0 disease
(88.3%) and pT1N1 disease did not differ significantly
FIGURE 3. (a) Cumulative survival of patients with pT3N0 gastric cancer is
illustrated according to the number of total retrieved lymph nodes (tLNs).
Patients with pT3N0 disease who had <31 tLNs (25th percentile) had a 10-
year survival rate (10-YSR) of 55.5% (n 5 102 patients); the other patients
with pT3N0 disease had a 10-YSR of 65.8% (n 5 339 patients; P 5 .108).
(b) Cumulative survival of patients with pT3N0 disease is illustrated for
patients who had <31 tLNs compared with patients who had pT3N1 disease.
The 10-YSR for patients with pT3N0 disease who had <31 tLNs was 55.5%
(n 5 102 patients); the 10-YSR for patients with pT3N1 disease was 53.7%
(n 5 677 patients; P 5 .314). (c) Cumulative survival of the patients from a
and b combined.
FIGURE 2. Cumulative survival according to each lymph node (N) stage.
The 10-year survival rate for the N0, N1, N2, and N3 subgroups was 62.9%,
53.3%, 29.1%, and 9.1%, respectively (P < .001). The 5-year survival rate
for these groups was 74.0%, 59.8%, 36.7%, and 14.4%, respectively
(P < .001).
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(P 5 .172), which rendered the similarity less mean-
ingful. The patients with pT2N0 disease who
had <31 tLNs had a better prognosis than the
patients with pT2N1 disease (84.1% vs 66.9%;
P < .001).
In multivariable analysis, age (P < .001), sex
(P 5 .042), location of the primary tumor (P 5 .006),
and the number of mLNs and tLNs (both P < .001)
emerged as independent risk factors. In the N0 and
N1 groups, the number of tLNs was not an inde-
pendent prognostic predictor. In the N2 subgroup,
an increasing number of tLNs was associated with a
better prognosis (P 5 .001; hazards ratio, 0.986; 95%
CI, 0.978–0.994). In the N3 subset, the number of
tLNs also was a favorable independent prognostic
factor (P 5 .008; hazards ratio, 0.988; 95% CI, 0.980–
0.997) (for details, see Table 3).
DISCUSSION
In the current study, we focused on patients with
pT3 gastric cancer, in whom lymph node metastasis
can increase markedly in the final staging from stage
II to stage III or even to stage IV, dramatically affect-
ing their prognosis.5,6 Inappropriate stage migration
can lead to inaccurate survival predictions and
sometimes can change the strategy of adjuvant ther-
apy.13 Because all patients who had pT4 disease were
diagnosed with stage IV gastric cancer, we excluded
them patients from the current study. Although such
patients also have a high risk of developing lymph
node metastasis, the effect of lymph node involve-
ment on their survival is relatively weak.14,15
In this study, we observed a positive linear cor-
relation between tLNs and mLNs (P < .001;
R2 5 0.091); patients who had <31 tLNs (25th quar-
tile) had less advanced N-stage disease (P < .001).
Furthermore, in a logistic regression model, the
number of tLNs (defined as a continuous variable)
emerged as one of the independent risk factors for
lymph node involvement, along with certain clinical
pathologic features (sex, Bormann type, and size of
the tumor). We observed a positive relation between
more tLNs and a greater chance to identify lymph
node metastases in patients with pT3 gastric cancer,
but not in patients with pT1 or T2 disease.
In our survival analyses, we observed an interest-
ing phenomenon: Although different survival could
be distinguished in patients with pT3N0 through
pT3N3 disease according to the fifth edition of the
UICC classification, the patients with pT3N0 disease
who had <31 tLNs had a 10-YSR similar to that for
the patients who had pT3N1 disease (55.4% and
53.3%, respectively; P 5 .207) compared with the
other N0 patients (65.8%; P 5 .108). However, none
of the clinical pathologic features that were analyzed
differed significantly between the 3 groups. There are
2 possible explanations for this observation. First,
there may have been lymph node metastases that
were missed during dissection or pathologic exami-
nation in N0 patients who had <31 tLNs, which may
have caused inappropriate understaging.16,17 Second,
there may be a therapeutic benefit from more exten-
sive lymph node dissection.17 More tLNs or a lower
TABLE 3
Multivariate Survival Analyses of Clinical and Pathologic Factors*
Variable P HR 95% CI
Overall
Age <.001 1.01 1.007–1.019
Sexy .042 1.148 1.005–1.310
Location .006
Upper third{ .069 1.179 0.988–1.407
Middle third{ .629 1.034 0.902–1.186
Diffuse{ .001 2.036 1.317–3.148
mLNs <.001 1.059 1.054–1.064
tLNs <.001 0.992 0.988–0.996
pT3N0
Age .036 1.015 1.001–1.029
Location .009
Upper third{ .908 1.026 0.667–1.578
Middle third{ .370 0.854 0.605–1.206
Diffuse{ .002 9.863 2.345–41.477
tLNs§ .326
pT3N1
Age <.001 1.021 1.010–1.031
Location .004
Upper third{ .001 1.676 1.230–2.284
Middle third{ .015 1.358 1.062–1.737
Diffuse{ .116 2.237 0.819–6.110




Upper third{ .273 1.204 0.864–1.678
Middle third{ .053 0.779 0.605–1.003
Diffuse{ .002 6.713 2.037–22.124
mLNs <.001 1.086 1.038–1.137
tLNs .001 0.986 0.978–0.994
pT3N3
Age .008 1.015 1.004–1.026
mLNs <.001 1.040 1.030–1.050
tLNs .008 0.988 0.980–0.997
HR indicates hazards ratio; 95% CI, 95% confidence interval; mLNs, metastatic lymph nodes; tLNs,
total retrieved lymph nodes; pT, pathologic tumor classification; N, lymph node status.
* Variables that were entered into the regression model were age, sex, macroscopic (Bormann) type,
location, size, histologic type, number of mLNs, and number of tLNs. Age, size, number of mLNs,
and number of tLNs were consecutive variables; others were categorized variables.
y Men compared with women.
{ Compared with the lower third.
§ Because tLNs did not emerged as an independent risk factor, the HR was not given.
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lymph node ratio is associated with a better progno-
sis.3,6,11,18,19 In the current study, however, the num-
ber of tLNs was not an independent predictor of
survival for patients with N0 or N1 disease. There-
fore, therapeutic benefit is not the likely cause for
the similarity in 10-YSR; instead, it is likely that the
similarity can be attributed primarily to stage migra-
tion.
Stage migration and survival have been studied
extensively in the context of cancer diagnosis and
treatment.20–22 More tLNs should increase the oppor-
tunity to find mLNs, sometimes leading to unneces-
sary upstaging, and may improve the survival for
each subgroup without changing a single patient’s
prognosis: the so-called Will Rogers phenomenon.23
However, in our study, the situation was a little dif-
ferent. The patients with N0 disease who had <31
tLNs (who were supposed to have a better prognosis)
had a survival rate similar to that of the N1 patients.
Thus, we believe that this is a problem of inappropri-
ate understaging rather than upstaging. Some of the
patients with N0 disease who had <31 tLNs actually
may have been patients with positive lymph node
status who had too few lymph nodes dissected and/
or examined. The potential mixture of these patients
with the patients who had genuine N0 status may
have decreased the survival rate for this particular
subgroup. Of course, this also could happen in the
patients with > 31 tLNs, although the possibility
would be much lower. This is consistent with the
positive correlation between tLNs and mLNs that we
demonstrated in this study. Although we cannot pro-
vide direct evidence, such as additional pathologic
examinations, this hypothesis is the most probable
explanation.
Several previous studies suggested that staging is
reliable when> 10 or 15 lymph nodes are exam-
ined.10,24 However, those studies examined all
patients. For the current report, we focused only on
patients with pT3 gastric cancer who had an extre-
mely high incidence of lymph node metastasis. We
failed to distinguish the patients with N0 disease
who had< 31 tLNs from the patients with N1 disease
in our survival analyses. Furthermore, our additional
evaluation of patients with pT1 and pT2 disease
revealed no positive correlation between the number
of tLNs and identifying lymph node metastasis. Our
survival analyses also produced no particular finding
in the pT1 subgroup: Because the survival of all
patients with pT1N0 and pT1N1 disease did not dif-
fer significantly, it was not meaningful to examine
the similarity of survival between patients with
pT1N0 disease who had <31 tLNs and patients with
pT1N1 disease. Thus, this routine cut-off value of 15
tLNs, which may be enough for the staging of
patients with pT1 and pT2 gastric cancer, was not
adequate for the correct staging of patients with
pT3N0 disease. This may not be easy for Western
surgeons to adopt; because, in their population, gas-
tric cancer is not a common disease, and fewer
lymph nodes are dissected compared with the num-
ber dissected by Eastern surgeons.3,5,6,24 The Western
cut-off value also may be different because of differ-
ent knowledge and different therapeutic patterns of
the disease. When we compared patients with N1
versus N2 disease or patients with N2 versus N3 dis-
ease, there was no similar finding, which indicates
that analyzing 15 lymph nodes in patients who have
confirmed lymph node involvement may be enough
to distinguish between N1, N2, and N3. Because the
presence of lymph node metastasis is hard to detect
preoperatively, all patients who have pT3 gastric can-
cer should undergo thorough lymph node dissection
and careful pathologic examination. Unfortunately,
we could not determine an optimal cut-off value for
accurate staging based on our data. Further prospec-
tive studies in cooperation with a pathology depart-
ment should be conducted. A strategy of comparing
N stage by gradually adding the number of lymph
nodes examined from the same specimen could illu-
minate the benefit from obtaining an increased num-
ber of tLNs on N staging and provide an appropriate
number of lymph nodes to be analyzed in patients
with pT3 gastric cancer.
In all patients with pT3 gastric cancer, and parti-
cularly in the subsets of patients with pT3N2 and N3
disease, the number of tLNs was an independent
prognostic predictor. All hazards ratios were <1, indi-
cating that an increased number of tLNs is asso-
ciated with a better prognosis. When we compared
the survival of patients between those with <31 tLNs
and those with >31 tLNs, the number tLNs only
reached statistical significance in univariate analyses
for the N2 subset (P 5 .0.027; 5-YSR, 29.9% compared
with 38.8%; data not shown). However, we believe
that a greater number of tLNs will lead to a better
prognosis. Because there are several factors that can
affect survival, the results of multivariate analyses
are more credible. Unlike other studies in which a
survival benefit usually is absent for patients with
advanced disease,6,11 we observed that greater num-
bers of dissected lymph nodes could lead to a better
prognosis in patients with pT3N2 disease and even
in patients with pT3N3 disease. This observation
may have been because we set the number of tLNs
as a consecutive variable rather as a categorized vari-
able, as in previous studies, thus preventing a loss of
information. This indicates the important impact of
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thorough lymph node dissection on survival, even in
patients with pT3N3 gastric cancer, who many
believed had incurable disease. However, this
remains unclear, and a randomized prospective study
should be performed.
We also wondered why tLNs did not emerge as in-
dependent prognostic predictor of survival in the N1
group. It is possible that the role of systemic lymph
node dissection was limited for patients with localized
disease; further studies should be conducted to clarify
this issue. Because we could not know the exact N
stage before surgery, a radical lymph node dissection
was mandatory in all patients.
In conclusion, increasing the number of tLNs
could improve the accuracy of N staging in patients
with pT3 gastric cancer, and especially in patients with
pT3N0 disease. The routine cut-off value of 15 lymph
nodes examined should be increased in staging pT3N0
lesions. More tLNs also may be associated with a better
prognosis in patients with pT3N2 and pT3N3 disease.
Because preoperative lymph node staging is difficult, a
thorough lymph node dissection and careful pathologic
examination should be performed in all patients who
may be serosa-positive.
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